Domain and Merck Serono in Parkinson's alliance
Domain Therapeutics of France has signed an exclusive development and licensing agreement with Merck Serono (Merck KgaA) targeting Parkinson's disease and other neurodegenerative diseases.
Domain Therapeutics of France has signed an exclusive development and licensing agreement with Merck Serono (Merck KgaA) targeting Parkinson's disease and other neurodegenerative diseases.